Prescription Required
Formulation: Film Coated Tablet
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: Film Coated Tablet
(Generic Alternative)
Select the prescribed dosage
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Kaletra is a prescription antiretroviral medication used to treat human immunodeficiency virus type 1 (HIV-1) infection.
It contains two active ingredients: lopinavir and ritonavir. These medications work together to reduce the amount of HIV in the body and help keep the virus under control.
Kaletra is not used by itself. It is taken together with other antiretroviral medications as part of a complete HIV treatment regimen.
Kaletra is used to treat HIV-1 infection in adults and pediatric patients.
Its main purpose is to reduce the amount of HIV in the blood, also known as the viral load. Lowering the viral load helps protect the immune system and supports the body’s ability to fight infections.
Kaletra may be prescribed as part of an initial HIV treatment plan or in certain patients who have previously used other antiretroviral medications.
HIV attacks certain immune cells, especially CD4 cells, which play an important role in helping the body fight infections.
Without effective treatment, HIV can continue multiplying and gradually reduce the number of healthy CD4 cells. This weakens the immune system and increases the risk of infections and other HIV-related complications.
Antiretroviral treatment helps stop HIV from reproducing and allows the immune system to remain stronger.
Kaletra belongs to a class of HIV medications known as protease inhibitors.
HIV produces long chains of proteins when it replicates. The virus uses an enzyme called protease to cut these proteins into smaller pieces that are needed to create mature and infectious virus particles.
Lopinavir blocks the HIV protease enzyme. When protease is inhibited, newly produced virus particles cannot mature properly and are less able to infect other cells.
This helps slow the spread of HIV within the body.
Lopinavir is the primary antiviral ingredient in Kaletra.
It directly inhibits HIV protease, preventing the virus from properly processing the proteins it needs to form mature virus particles.
By interfering with this stage of the HIV life cycle, lopinavir reduces the virus’s ability to reproduce and spread.
Ritonavir is also a protease inhibitor, but its main purpose in Kaletra is to increase the effectiveness of lopinavir.
The liver normally breaks down lopinavir relatively quickly. Ritonavir blocks an enzyme involved in this process, allowing lopinavir to remain in the bloodstream at higher concentrations for a longer period.
This is sometimes called a “boosting” effect. By boosting lopinavir levels, ritonavir helps maintain an effective amount of the medication in the body.
When taken consistently with other antiretroviral medications, Kaletra helps prevent HIV from making new mature virus particles.
As viral replication decreases, the amount of HIV circulating in the blood can fall. This reduction is measured through viral load testing.
The goal of HIV treatment is generally to reduce the viral load to an undetectable level and keep it suppressed over time.
Lowering the viral load reduces the ongoing damage HIV can cause to the immune system.
As the virus becomes controlled, CD4 cell levels may increase or remain more stable. A stronger CD4 count helps the body defend itself against infections and other illnesses.
Healthcare providers commonly monitor both viral load and CD4 counts to evaluate how well HIV treatment is working.
HIV treatment typically involves several antiretroviral medications that target the virus at different stages of its life cycle.
Using multiple medications together provides stronger viral suppression and helps reduce the likelihood that HIV will develop resistance to treatment.
Your healthcare provider will choose the other medications used with Kaletra based on factors such as previous HIV treatment, resistance testing, other medical conditions, and possible drug interactions.
Drug resistance occurs when HIV changes in a way that allows it to continue multiplying despite the presence of an antiretroviral medication.
Missing doses, stopping treatment, or taking HIV medications inconsistently can allow the virus to reproduce and increase the risk of resistance.
If resistance develops, some medications may become less effective or stop working altogether.
Taking Kaletra and the other medications in your HIV regimen exactly as prescribed is therefore an important part of successful treatment.
No. Kaletra does not cure HIV.
Antiretroviral therapy controls the virus but does not completely remove it from the body. HIV remains present even when the viral load becomes undetectable.
For this reason, treatment usually needs to continue long term unless a healthcare provider recommends changing the medication regimen.
An undetectable viral load means that the amount of HIV in the blood has been reduced to a level that standard laboratory tests cannot detect.
Maintaining an undetectable viral load helps protect the immune system and greatly reduces the risk of HIV-related complications.
People who maintain an undetectable viral load through effective treatment also do not sexually transmit HIV, commonly described as “Undetectable = Untransmittable” or U=U.
Regular medical follow-up is an important part of treatment with Kaletra.
Your healthcare provider may perform blood tests to monitor your viral load, CD4 count, liver function, cholesterol and triglyceride levels, blood sugar, and other health indicators.
These tests help determine how well treatment is working and whether any changes to your medication regimen are necessary.
HIV treatment is generally long term.
Continue taking Kaletra and your other antiretroviral medications exactly as prescribed, even if you feel well or your viral load becomes undetectable.
Stopping treatment without medical guidance can allow HIV to multiply again, increase the viral load, lower CD4 levels, and increase the risk of drug resistance.
Kaletra is taken by mouth and is available in tablet form. Depending on the treatment plan, adults may take it once or twice daily.
Kaletra tablets can generally be taken with or without food. Swallow the tablets whole with water and do not crush, chew, or break them.
Try to take each dose at the same time every day. Maintaining a consistent schedule helps keep the amount of medication in your body steady and supports continuous control of HIV.
Kaletra works best when it is taken exactly as prescribed.
Skipping doses, taking doses late, or stopping treatment can allow HIV to multiply again. This may cause the viral load to increase and can make it easier for the virus to develop resistance to the medication.
Drug resistance can reduce the effectiveness of Kaletra and may limit future HIV treatment options.
If you have trouble following your medication schedule, speak with your healthcare provider or pharmacist rather than changing the regimen on your own.
Taking more Kaletra than prescribed will not improve HIV control and may increase the risk of side effects.
Always follow the dose and schedule provided by your healthcare provider. Do not double your dose after a missed dose unless specifically instructed to do so.
If you accidentally take more than prescribed, contact a healthcare provider or poison control center for guidance.
If Kaletra is used together with didanosine, special attention may be needed when scheduling the medications.
Kaletra tablets may be taken at the same time as didanosine, but didanosine is generally taken on an empty stomach.
Follow the instructions provided by your doctor or pharmacist so that both medications are taken correctly.
The appropriate dose of Kaletra depends on several factors.
Your healthcare provider may consider your age, body weight, treatment history, viral resistance profile, other medical conditions, and any medications you are taking.
Some medicines can significantly change the amount of lopinavir or ritonavir in the body, so your doctor may need to adjust your treatment regimen or avoid certain drug combinations.
The recommended total daily dose for many adults is 800 mg of lopinavir and 200 mg of ritonavir.
Depending on the patient, this may be given as:
Once-daily dosing is only appropriate for certain patients.
Your healthcare provider will decide whether once- or twice-daily dosing is suitable based on factors such as previous treatment, viral resistance, and other medications.
Once-daily Kaletra is not recommended for every patient.
People with certain lopinavir-associated resistance mutations, some patients taking interacting medications, pediatric patients, and pregnant patients may need twice-daily dosing instead.
Your healthcare provider will select the dosing schedule that provides the most reliable viral suppression for your situation.
Kaletra may be used in pediatric patients 14 days of age and older.
Once-daily dosing is not recommended for children. Pediatric doses are usually given twice daily and are calculated according to body weight or body surface area.
Because children grow and gain weight, the dose may need to be recalculated periodically.
Regular follow-up allows the healthcare provider to make sure the child continues receiving an appropriate amount of medication.
Very young infants require especially careful dosing because their bodies process medications differently from older children and adults.
For infants 14 days to 6 months of age, dosing is usually based on body weight or body surface area and is given twice daily.
Treatment in this age group should be closely managed by a healthcare provider experienced in pediatric HIV care.
Pregnant patients generally require twice-daily dosing.
For pregnant patients without documented lopinavir-associated resistance substitutions, a commonly recommended dose is 400 mg of lopinavir and 100 mg of ritonavir twice daily.
Once-daily dosing is not recommended during pregnancy.
Your healthcare provider may monitor viral load and treatment response more closely throughout pregnancy to help maintain effective viral suppression.
Your dose or treatment schedule may change over time.
Changes may be needed because of new medications, side effects, pregnancy, changes in weight, laboratory results, or evidence that the virus has developed resistance.
Never adjust the dose on your own. Any change should be made under the guidance of your healthcare provider.
Ritonavir strongly affects liver enzymes that process many medications.
Because of this, Kaletra can interact with a large number of prescription drugs, over-the-counter medicines, supplements, and herbal products.
Some combinations can increase side effects, while others can reduce the effectiveness of Kaletra or another medication.
Before starting Kaletra, give your healthcare provider a complete list of everything you take.
If you miss a dose of Kaletra, take it as soon as you remember unless it is almost time for your next scheduled dose.
If your next dose is close, skip the missed dose and return to your regular schedule.
Do not take two doses at the same time to make up for a missed dose.
Because repeated missed doses can increase the risk of HIV resistance, contact your healthcare provider if you are frequently missing doses.
Do not stop Kaletra or any other HIV medication without first speaking with your healthcare provider.
Stopping treatment can allow HIV to begin multiplying again. This may increase your viral load, reduce CD4 cell levels, and increase the chance that the virus develops resistance.
If side effects are making it difficult to continue treatment, contact your healthcare provider. Your regimen may be adjusted without unnecessarily interrupting HIV treatment.
Regular monitoring helps determine whether Kaletra is controlling HIV effectively and whether it is causing any unwanted effects.
Your healthcare provider may periodically check your viral load, CD4 cell count, liver function, blood sugar, cholesterol, triglycerides, and other laboratory values.
These results can help guide treatment decisions and identify problems early.
HIV treatment is generally long term.
Continue taking Kaletra and the other antiretroviral medications in your regimen every day, even if you feel well or your viral load becomes undetectable.
An undetectable viral load means the treatment is working, not that HIV has been eliminated from the body. Staying consistent with treatment is important for maintaining viral suppression.
Kaletra (Lopinavir/Ritonavir) is available in the following forms and strength:
Kaletra must be taken consistently and exactly as prescribed. Missing doses, stopping treatment, or taking the medication incorrectly may allow HIV to multiply and increase the risk of developing drug resistance.
Resistance may make Kaletra less effective and can sometimes cause cross-resistance, meaning other medications in the same drug class may also become less effective.
Kaletra may cause liver problems, including increases in liver enzymes and, in rare cases, serious liver damage.
The risk may be greater in people who already have liver disease or certain liver infections. Your healthcare provider may perform blood tests to monitor liver function before and during treatment.
Contact your doctor if you develop symptoms such as yellowing of the skin or eyes, dark urine, unusual tiredness, loss of appetite, nausea, or pain in the upper right side of the abdomen.
Cases of pancreatitis, or inflammation of the pancreas, have been reported in people taking Kaletra.
Symptoms may include severe or persistent abdominal pain, nausea, and vomiting. The pain may sometimes spread to the back.
Seek medical attention promptly if you develop symptoms that could indicate pancreatitis.
Kaletra may affect the electrical activity of the heart and can increase the risk of abnormal heart rhythms in some patients.
Tell your healthcare provider if you have a history of heart rhythm problems, heart disease, or if you take medications that can affect heart rhythm.
Seek medical attention if you experience fainting, severe dizziness, or a fast or irregular heartbeat.
Kaletra may increase blood glucose levels or make existing diabetes more difficult to control.
Some patients taking protease inhibitors have developed new or worsening high blood sugar. Symptoms may include increased thirst, frequent urination, increased hunger, or unexplained tiredness.
Your healthcare provider may monitor your blood sugar during treatment, particularly if you already have diabetes or other risk factors.
Some people receiving antiretroviral treatment may notice changes in the amount or location of body fat.
These changes can vary between individuals. Tell your healthcare provider if you notice significant or unusual changes while receiving HIV treatment.
Kaletra can interact with many other medications because ritonavir strongly affects the enzymes responsible for processing certain drugs.
Interactions may occur with some blood thinners, cholesterol-lowering medications, heart medications, migraine treatments, sedatives, seizure medications, and other prescription drugs.
Some interactions can cause serious or potentially life-threatening effects. Tell your doctor and pharmacist about all prescription medications, over-the-counter products, vitamins, supplements, and herbal products you use before starting Kaletra.
Do not start or stop another medication without first checking with your healthcare provider.
Tell your healthcare provider if you have kidney disease or liver disease before starting Kaletra.
Liver disease is particularly important because lopinavir and ritonavir are processed primarily by the liver. Patients with liver impairment may require closer monitoring during treatment.
Your healthcare provider will determine whether Kaletra is appropriate based on your medical condition and laboratory results.
Kaletra may cause skin reactions, including rash.
In some cases, a rash may be part of a more serious allergic reaction. Seek immediate medical attention if a rash occurs together with symptoms such as swelling of the face, lips, tongue, or throat, difficulty breathing, blistering, or severe skin peeling.
People with hemophilia may experience increased bleeding while taking protease inhibitors such as Kaletra.
Tell your healthcare provider if you have hemophilia or another bleeding disorder before starting treatment.
Contact your doctor if you notice unusual or increased bleeding.
People living with HIV may experience changes in bone mineral density for several reasons, including HIV infection itself and the effects of some antiretroviral treatment regimens.
Reduced bone density may increase the risk of osteoporosis and fractures.
Tell your healthcare provider if you have a history of osteoporosis, fractures, or other risk factors for bone loss. Your doctor can determine whether additional monitoring or preventive measures are appropriate.
If you are pregnant, planning to become pregnant, or think you may be pregnant, tell your healthcare provider before taking Kaletra.
Effective HIV treatment during pregnancy is important for maintaining the mother’s health and reducing the risk of HIV transmission to the baby. Whether Kaletra should be used depends on the patient’s treatment history, other medications, viral resistance, and individual clinical circumstances.
Kaletra should be used during pregnancy only under the direction and close supervision of a healthcare provider experienced in managing HIV during pregnancy.
Regular follow-up is important while taking Kaletra.
Your healthcare provider may monitor your HIV viral load, CD4 count, liver function, blood glucose, cholesterol, triglycerides, and other laboratory values throughout treatment.
These tests help determine whether the medication is controlling HIV effectively and allow potential side effects or complications to be identified early.
Kaletra may be used during pregnancy when a healthcare provider determines that it is appropriate. For pregnant patients without documented lopinavir-associated resistance substitutions, a commonly recommended dose is 400 mg of lopinavir and 100 mg of ritonavir twice daily. Once-daily dosing is generally not recommended during pregnancy. Treatment should be closely supervised by a healthcare provider experienced in managing HIV during pregnancy.
Yes. Kaletra can interact with many medications because ritonavir affects the way certain drugs are broken down in the body. Potential interactions may occur with some blood thinners, cholesterol-lowering medications, migraine treatments, heart medications, seizure medications, sedatives, and other prescription drugs. Before starting Kaletra, tell your doctor and pharmacist about all prescription medications, over-the-counter drugs, vitamins, supplements, and herbal products you use.
Kaletra tablets do not need to be refrigerated and can generally be stored at room temperature according to the storage instructions on the product label. Kaletra oral solution should preferably be refrigerated at 2°C to 8°C (36°F to 46°F). If stored at room temperature below 25°C (77°F), it should generally be used within 2 months. Keep Kaletra away from excessive heat and follow the storage instructions provided by your pharmacist or on the medication label.
Kaletra tablets can be taken with or without food. However, the oral solution should be taken with food because food helps improve the absorption of lopinavir and ritonavir. Always follow the instructions for the specific Kaletra formulation you have been prescribed.
| Generic name: | Lopinavir/Ritonavir |
|---|---|
| Formulation: | Film Coated Tablet, Tablet |
| Strength(s): | 200/50mg |
| Quantities Available: | 60, 120 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Kaletra (lopinavir/ritonavir) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of conditions like HIV without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Kaletra is commonly prescribed in tablets containing lopinavir/ritonavir in strengths such as 200 mg/50 mg, taken twice daily. For a 90-day supply, this means you would order 180 tablets (90 days x 2 tablets per day).
Yes, we do sell lopinavir/ritonavir on our website. You can enjoy competitive prices for this medication. To purchase lopinavir/ritonavir from us, you will need a valid prescription from your healthcare provider. We require this to dispense the medication safely and legally. You can conveniently submit your prescription by mail, fax, or upload it through your online account.
Yes, we ship Kaletra (lopinavir/ritonavir) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Kaletra (Lopinavir/Ritonavir). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Kaletra (Lopinavir/Ritonavir).
REVIEWS